0000000001228907

AUTHOR

Loretta D'onofrio

showing 4 related works from this author

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

2020

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 70…

0301 basic medicineOncologyPhysiologyReceptor ErbB-2Clinical BiochemistryAdo-Trastuzumab EmtansineSettore MED/06body mass index; HER2-positive metastatic breast cancer; pertuzumab; trastuzumab emtansinechemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalAged 80 and overeducation.field_of_studyUnivariate analysisMiddle AgedMetastatic breast cancerProgression-Free SurvivalQuartile030220 oncology & carcinogenesisHER2-positive metastatic breast cancerDisease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialtyPopulationBreast Neoplasmsbody mass indexAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineHumansObesityeducationAgedtrastuzumab emtansinebusiness.industrynutritional and metabolic diseasesCell BiologyOverweightmedicine.disease030104 developmental biologychemistryTrastuzumab emtansineMED/06 - ONCOLOGIA MEDICAbusinessBody mass index
researchProduct

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Reg…

2015

Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic database…

OncologyGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularPrognosiConcordancePopulationMEDLINElcsh:MedicineCarcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Cochrane LibraryBiochemistryInternal medicinemedicineHumanseducationlcsh:ScienceSurvival analysiseducation.field_of_studyMultidisciplinaryBiochemistry Genetics and Molecular Biology (all)Carcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)business.industryMedicine (all)CarcinomaLiver Neoplasmslcsh:RHepatocellularPrognosisSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeAgricultural and Biological Sciences (all)Response Evaluation Criteria in Solid TumorsLiver NeoplasmMeta-analysislcsh:QSurvival AnalysibusinessHumanResearch ArticlePLoS ONE
researchProduct

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HE…

2020

We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression‐free survival at first‐line (mPFS1) was 12 months. Pertuzumab as first‐line conferred longer mPFS1 compared to other first‐line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second‐line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T‐DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing b…

OncologyCancer ResearchMultivariate analysisSettore MED/06 - Oncologia MedicaReceptor ErbB-2T-DM1Estrogen receptor0302 clinical medicineErbB-2TrastuzumabReceptorsAntineoplastic Combined Chemotherapy Protocols80 and overMolecular Targeted TherapyNeoplasm MetastasisCancer Therapy and PreventionProgesteroneAged 80 and overadvanced breast cancerTumorreal worldMiddle AgedPrognosisMetastatic breast cancerImmunohistochemistryGene Expression Regulation NeoplastictrastuzumabOncologyReceptors Estrogen030220 oncology & carcinogenesisImmunohistochemistryFemaleadvanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Breast Neoplasms; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Gene Expression Regulation NeoplasticPertuzumabReceptors ProgesteroneHER2 positive; T-DM1; advanced breast cancer; pertuzumab; real world; trastuzumabmedicine.drugReceptorAdultHER2 positivemedicine.medical_specialtyT‐DM1advanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; chemotherapyBreast Neoplasms03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineBiomarkers TumorHumansAgedNeoplasm StagingNeoplasticbusiness.industrymedicine.diseaseEstrogenSettore CHIM/08 - Chimica FarmaceuticaGene Expression RegulationMED/06 - ONCOLOGIA MEDICAbusinessBiomarkersHormone
researchProduct

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

2017

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreat…

0301 basic medicineOncologyHER2 positivereal-worldmedicine.medical_specialtyHER2 positive; T-DM1; metastatic breast cancer; previous pertuzumab; real-worldHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1; OncologyT-DM1Previous pertuzumabHER2 positive; metastatic breast cancer; previous pertuzumab; real-world; T-DM1; oncologyECOG Performance Statuslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialSettore MED/04 - PATOLOGIA GENERALElawInternal medicineMedicineUnivariate analysisSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerprevious pertuzumabmedicine.diseaseMetastatic breast cancerMetastatic breast cancerHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1Log-rank testtrastuzumab030104 developmental biologyOncologychemistryReal-worldTrastuzumab emtansine030220 oncology & carcinogenesisHER2 positive Metastatic breast cancer Previous pertuzumab Real-world T-DM1 Oncologymetastatic breast cancerPertuzumabbusinessmedicine.drugResearch Paper
researchProduct